Biotechnologie 23 Srpen 2025 - 29 Leden 2026

U.S. senators move to police synthetic DNA sales as bioweapon fears sharpen
·

Američtí senátoři chtějí regulovat prodej syntetické DNA kvůli rostoucím obavám z biologických zbraní

Two U.S. senators introduced a bill requiring the Commerce Department to regulate synthetic DNA sales and mandate customer screening for dangerous genetic sequences. The proposal orders a federal list of “sequences of concern,” compliance audits, and civil penalties up to $750,000. It also calls for a NIST “governance sandbox” and federal oversight review of biosecurity.
5 února, 2026
Neuron Xenotransplantation
··

Prasečí neurony v lidském mozku? Realita roku 2025 v xenotransplantaci neuronů—průlomy, rizika a co nás čeká dál

The FDA approved the first clinical trials of kidney xenotransplantation in 2024. Preclinical studies show pig neuron precursors can function in rodents and marine mammals, while human neurons integrate in animal brains for research. No neuron xenotransplants have been performed in patients. Advances in gene editing and immune protection have improved safety for all xenotransplantation.
23 září, 2025
Groundbreaking treatments - super crops - and a revolution in green technology
··

Biotechnologie 2025: Průlomové léky, superplodiny a revoluce zelených technologií

The global biotechnology market is projected to grow from $483 billion in 2024 to $546 billion in 2025, a 13% increase. Casgevy gene therapy for sickle cell disease and beta-thalassemia is expected to reach patients in 2025. Novo Nordisk and Eli Lilly are investing billions to address U.S. shortages of GLP-1 drugs. Over 60% of new crop varieties in 2025 use CRISPR technology.
23 srpna, 2025

Stock Market Today

  • Diploma Plc: £10,000 in FTSE 100 Stock Grew to £23,959 Over 5 Years
    May 25, 2026, 11:41 AM EDT. Diploma Plc (LSE:DPLM) has been a top FTSE 100 performer, turning a £10,000 investment five years ago into £23,959. The company reported 17% revenue growth and a 36% rise in earnings per share recently, driven largely by its Controls division, which benefits from increased defence spending and data centre demand. Despite this strong performance, risks persist due to the company's reliance on cyclical markets like aerospace and data centres. With a high price-to-earnings (P/E) ratio around 31, the stock could face sharp declines if demand falters. Analysts urge caution, noting that the firm's target of 5% annual organic growth may not justify its current valuation.